Kidney transplant trial tests which drug better prevents rejection
NCT ID NCT05385432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial compares two induction therapies—rabbit anti-thymocyte globulin (rATG) and basiliximab—in 244 sensitized kidney transplant recipients who do not have pre-existing donor-specific antibodies. The goal is to see which drug better prevents biopsy-proven acute rejection within the first year after transplant. Participants will receive standard maintenance immunosuppression alongside the assigned induction therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rabbit anti-thymocyte globulin (rATG) and basiliximab
- What this could lead to
- If successful, this trial could show which induction therapy is safer and more effective for preventing kidney transplant rejection in sensitized patients without donor-specific antibodies.
- What could go wrong
- This is a phase 3 trial, but results may not apply to all patients. Both drugs have known risks like infection and side effects, and the benefit of one over the other may be small or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
01-TOURS
RECRUITINGTours, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- A regenerative graft could rethink dialysis access
- Pumpkin seed oil may fight inflammation in kidney patients — a trial puts it to the test